Approved Ligands

Tirofiban (MK-383) is a selective palate GPIIb/IIIa antagonist which inhibits platelet aggregation with IC50 of 9 nM.

Tirofiban (MK-383) is a selective palate GPIIb/IIIa antagonist which inhibits platelet aggregation with IC50 of 9 nM.

Tirofiban (MK-383) is a selective palate GPIIb/IIIa antagonist which inhibits platelet aggregation with IC50 of 9 nM.

Tivozanib (AV-951) is a potent and selective VEGFR inhibitor for VEGFR1/2/3 with IC50 of 30 nM/6.5 nM/15 nM, and also inhibits PDGFR and c-Kit, low activity observed against FGFR-1, Flt3, c-Met, EGFR and IGF-1R.

Tivozanib (AV-951) is a potent and selective VEGFR inhibitor for VEGFR1/2/3 with IC50 of 30 nM/6.5 nM/15 nM, and also inhibits PDGFR and c-Kit, low activity observed against FGFR-1, Flt3, c-Met, EGFR and IGF-1R.

Tivozanib (AV-951) is a potent and selective VEGFR inhibitor for VEGFR1/2/3 with IC50 of 30 nM/6.5 nM/15 nM, and also inhibits PDGFR and c-Kit, low activity observed against FGFR-1, Flt3, c-Met, EGFR and IGF-1R.

Potent, cell-permeable/xa0Janus kinase (JAK) inhibitor.

Potent, cell-permeable/xa0Janus kinase (JAK) inhibitor.

Potent, cell-permeable/xa0Janus kinase (JAK) inhibitor.

Potent, cell-permeable/xa0Janus kinase (JAK) inhibitor.

Potent, cell-permeable/xa0Janus kinase (JAK) inhibitor.

Tolbutamide is a sulfonylurea agonist for secretion of insulin by beta-cells. In rat pancreatic beta-cells cultured in the presence of Tolbutamide displayed increased numbers of beta-cells in a dose responsive manner with beta-cell numbers doubling